EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults—A randomized blinded controlled trial

Johannes Sumer, Karin Keckeis, Giulia Scanferla, Manuel Frischknecht, Julia Notter, Ana Steffen, Philipp Kohler, Patrick Schmid, Bianca Roth, Kerstin Wissel, Pietro Vernazza, Peter Klein und 2 weitere

Frontiers in Medicine · 17.04.2023 · 10

DOI: 10.3389/fmed.2023.948787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 17.04.2023. Verfasst von Johannes Sumer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Echinacea purpurea has clinical antiviral activity against respiratory viruses and modulates immune functions. In this study, we compared higher doses of new Echinacea formulations with conventional formulations at lower, preventive doses for therapy of respiratory tract infections (RTIs).

Methods

In this randomized, blinded, controlled trial, healthy adults ( n = 409) were randomized between November 2018 and January 2019 to one of four Echinacea formulations, which were taken in case of an RTI for up to 10 days. New formulations A (lozenges) and B (spray) delivered an increased dose of 16,800 mg/d Echinacea extract during days 1–3 and 2,240–3,360 mg/d afterward; as controls, conventional formulations C (tablets) and D (drops) delivered a lower daily dose of 2,400 mg, usually taken for prevention. The primary endpoint was time to clinical remission of first RTI episodes based on the Kaplan–Meier analysis of patient-reported, investigator-confirmed, respiratory symptoms assessed for up to 10 days. In a sensitivity analysis, the mean time to remission beyond day 10 was calculated by extrapolating the treatment effects observed on days 7 to 10.

Results

A total of 246 participants (median age 32 years, 78% female participants) were treated for at least one RTI. Recovery by day 10 (complete absence of symptoms) was achieved in 56 and 44% of patients with the new and conventional formulations, respectively, showing a median time to recovery of 10 and 11 days, respectively ( p = 0.10 in intention-to-treat analysis, p = 0.07 in per-protocol analysis). In the extrapolated sensitivity analysis, new formulations resulted in a significantly shorter mean time to remission (9.6 vs. 11.0 days, p < 0.001). Among those with an identified respiratory virus, viral clearance until day 10 based on real-time PCR from nasopharyngeal swabs was more frequent with new formulations (70 vs. 53%, p = 0.046). Tolerability and safety (adverse events: 12 vs. 6%, p = 0.19) were good and similar between formulations. There was one severe adverse event with a potential hypersensitivity reaction in a recipient of the novel spray formulation.

Conclusion

In adults with acute RTI, new Echinacea formulations with higher doses resulted in faster viral clearance than conventional formulations in prophylactic dosages. The trend for faster clinical recovery was not significant by day 10 but became so upon extrapolation. A dose increase during acute respiratory symptoms might improve the clinical benefits of orally administered Echinacea formulations.

Trial registration

The study was registered in the Swiss National Clinical Trials Portal (SNCTP000003069) and on ClinicalTrials.gov (NTC03812900; URL https://clinicaltrials.gov/ct2/show/NCT03812900?cond=echinacea&draw=3&rank=14 ).

Schlagwörter

Stichwörter der Autor:innen

Echinacea purpureaantiviralpharmaceutical formulationsrandomized controlled trialrespiratory tract infection

Autor:innen und Institutionen

  • Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital of Lucerne, Luzern, Switzerland.
  • Checkpoint Zürich, Zurich, Switzerland.
  • d.s.h. Statistical Services GmbH, Rohrbach, Germany.
  • A.Vogel AG, Roggwil, Switzerland.

Zitieren

APA

Sumer, J., Keckeis, K., Scanferla, G., Frischknecht, M., Notter, J., Steffen, A., Kohler, P., Schmid, P., Roth, B., Wissel, K., Vernazza, P., Klein, P., Schoop, R., & Albrich, W. C. (2023). Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults—A randomized blinded controlled trial. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.948787

Vancouver

Sumer J, Keckeis K, Scanferla G, Frischknecht M, Notter J, Steffen A, et al. Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults—A randomized blinded controlled trial. Frontiers in Medicine. 2023;10. doi:10.3389/fmed.2023.948787

BibTeX
@article{Sumer2023,
  author = {Sumer, Johannes and Keckeis, Karin and Scanferla, Giulia and Frischknecht, Manuel and Notter, Julia and Steffen, Ana and Kohler, Philipp and Schmid, Patrick and Roth, Bianca and Wissel, Kerstin and Vernazza, Pietro and Klein, Peter and Schoop, Roland and Albrich, Werner C},
  title = {Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults—A randomized blinded controlled trial},
  journal = {Frontiers in Medicine},
  year = {2023},
  volume = {10},
  doi = {10.3389/fmed.2023.948787}
}
Kostenlos starten →